Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2016 08:00 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences’ Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting

Oral presentation highlights specific improvements in negative symptoms and cognition observed in schizophrenic patients treated with MIN-101 in Phase IIB trial Data also presented from Phase IIA...